Millendo Therapeutics is considering a corporate reorganization after its lead drug, an investigational treatment for a rare genetic condition characterized by unrelenting hunger, did not perform better than a placebo in a pivotal trial.
The Ann Arbor, MI-based company said Monday that the drug, livoletide, did not meet the goal of the Phase 2b study evaluating it as a treatment for Prader-Willi syndrome. People with this condition—the most common genetic cause of life-threatening childhood obesity—have an insatiable appetite that leads to chronic overeating, or hyperphagia.
Millendo (NASDAQ: MLND) reported that livoletide, compared to a placebo, did not show a… Read more »
UNDERWRITERS AND PARTNERS
